Perritt Capital Management Inc Purchases New Stake in Biomerica, Inc. (NASDAQ:BMRA)

Perritt Capital Management Inc acquired a new stake in Biomerica, Inc. (NASDAQ:BMRA) during the second quarter, Holdings Channel.com reports. The fund acquired 70,000 shares of the company’s stock, valued at approximately $31,000.

Separately, Russell Investments Group Ltd. boosted its stake in Biomerica by 11.8% during the 1st quarter. Russell Investments Group Ltd. now owns 225,435 shares of the company’s stock valued at $188,000 after purchasing an additional 23,872 shares during the last quarter. 22.28% of the stock is currently owned by institutional investors and hedge funds.

Biomerica Stock Performance

Shares of BMRA opened at $0.31 on Thursday. Biomerica, Inc. has a 52 week low of $0.24 and a 52 week high of $2.13. The stock has a 50 day moving average price of $0.37 and a two-hundred day moving average price of $0.61. The firm has a market capitalization of $5.24 million, a P/E ratio of -0.84 and a beta of -1.09.

Biomerica Company Profile

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.